Author(s): Frank Morschhauser, Nathan H. Fowler, Pierre Feugier, et. al Abstract: S154 Session topic: 20. Indolent Non-Hodgkin lymphoma – Clinical Background Standard of care for advanced stage, high tumor burden, previously untreated follicular lymphoma (FL) has been rituximab plus chemotherapy (R-chemo) followed by rituximab maintenance. Combination immunotherapy with lenalidomide and rituximab (R2)...
Pro zobrazení tohoto obsahu je třeba být přihlášen.